Eagle Pharmaceuticals Inc (NASDAQ:EGRX) was the target of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 1,690,000 shares, a growth of 8.3% from the December 15th total of 1,560,000 shares. Currently, 12.9% of the shares of the stock are short sold. Based on an average trading volume of 133,700 shares, the days-to-cover ratio is currently 12.6 days.
A number of research analysts have recently weighed in on EGRX shares. Zacks Investment Research upgraded Eagle Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Friday, January 3rd. TheStreet downgraded Eagle Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Friday, November 22nd. ValuEngine cut Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, October 19th. Finally, BidaskClub cut Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, January 8th. Five research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Eagle Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $60.25.
Shares of NASDAQ:EGRX traded up $0.22 on Friday, reaching $59.77. The company had a trading volume of 310 shares, compared to its average volume of 183,392. Eagle Pharmaceuticals has a twelve month low of $38.38 and a twelve month high of $64.94. The stock has a 50-day moving average price of $58.97 and a 200 day moving average price of $57.99. The stock has a market capitalization of $802.29 million, a P/E ratio of 28.66 and a beta of 1.42. The company has a quick ratio of 4.07, a current ratio of 4.24 and a debt-to-equity ratio of 0.20.
Eagle Pharmaceuticals (NASDAQ:EGRX) last announced its quarterly earnings results on Tuesday, November 12th. The specialty pharmaceutical company reported $0.26 earnings per share for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.17). Eagle Pharmaceuticals had a return on equity of 16.07% and a net margin of 12.72%. The company had revenue of $41.10 million during the quarter, compared to analyst estimates of $45.44 million. During the same period in the prior year, the firm earned $1.18 EPS. Eagle Pharmaceuticals’s quarterly revenue was down 19.9% on a year-over-year basis. On average, sell-side analysts predict that Eagle Pharmaceuticals will post 1.45 earnings per share for the current fiscal year.
In related news, Director Hudson Executive Capital Lp sold 3,849 shares of Eagle Pharmaceuticals stock in a transaction on Monday, October 21st. The stock was sold at an average price of $62.56, for a total value of $240,793.44. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders sold a total of 19,486 shares of company stock worth $1,234,640 over the last 90 days. Insiders own 31.70% of the company’s stock.
Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. boosted its holdings in shares of Eagle Pharmaceuticals by 5.0% in the 2nd quarter. BlackRock Inc. now owns 1,743,694 shares of the specialty pharmaceutical company’s stock worth $97,089,000 after acquiring an additional 83,722 shares in the last quarter. Invesco Ltd. lifted its holdings in Eagle Pharmaceuticals by 50.4% during the 2nd quarter. Invesco Ltd. now owns 402,792 shares of the specialty pharmaceutical company’s stock worth $22,427,000 after buying an additional 134,931 shares in the last quarter. Smith Graham & Co. Investment Advisors LP lifted its holdings in Eagle Pharmaceuticals by 0.6% during the 3rd quarter. Smith Graham & Co. Investment Advisors LP now owns 154,654 shares of the specialty pharmaceutical company’s stock worth $8,749,000 after buying an additional 980 shares in the last quarter. Northern Trust Corp lifted its holdings in Eagle Pharmaceuticals by 0.4% during the 2nd quarter. Northern Trust Corp now owns 145,597 shares of the specialty pharmaceutical company’s stock worth $8,106,000 after buying an additional 529 shares in the last quarter. Finally, Morgan Stanley lifted its holdings in Eagle Pharmaceuticals by 94.0% during the 2nd quarter. Morgan Stanley now owns 142,256 shares of the specialty pharmaceutical company’s stock worth $7,921,000 after buying an additional 68,937 shares in the last quarter. Institutional investors and hedge funds own 95.25% of the company’s stock.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL.
Read More: Correction
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.